CPRX P/E Ratio Analysis
Updated 540h ago·SEC filings & market data
Key Takeaway
A P/E ratio of 17.4x means investors pay $17.40 for each $1 of the company's annual earnings.
Sector Performance
33th percentileCPRX
17.4x
Sector Median
23.1x
Sector Avg
33.8x
Prior Period
17.2x(Jun 2026)
Deep Analysis
A P/E ratio of 17.4x means investors pay $17.40 for each $1 of the company's annual earnings.
Among sector peers, this is below the sector median of 23.2x, placing CPRX at the 33rd percentile—cheaper than most comparable stocks. The metric is stable: over the last 8 quarters the trend is flat, with a quarter-over-quarter increase of +0.9% and no year-over-year change available. The combination of a below-median P/E and a stable trend suggests limited earnings multiple expansion, but also reduces the risk of a valuation-driven correction. This level implies a moderate risk profile: the stock is not expensive relative to peers, yet stable multiples offer little upside purely from re-rating. This metric supports the overall NEUTRAL verdict, as it neither flags an overvaluation risk nor signals a compelling bargain.
Frequently Asked Questions
What does the P/E Ratio tell investors about CPRX?
Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.
How is the P/E Ratio calculated?
P/E Ratio is calculated as: Price / EPS.
Who are CPRX's closest peers by P/E Ratio?
The closest peers by P/E Ratio include: CMCSA (7.8x), EG (7.8x), CHRD (7.7x), OXY (7.4x), THC (7.3x).
Learn More About P/E Ratio
The Formula
Price / EPS
Why It Matters
Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.
Master CPRX's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full CPRX research report →CPRX
17.4x
Sector Median
23.1x
Sector Avg
33.8x
How CPRX's P/E Ratio compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.